Prognostic impact of node involvement pattern in pN1 non-small cell lung cancer patients

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1576-1582

  Nakao, Masayuki ^a   Yoshida, Junji ^a   Ishii, Genichiro ^a   Kawase, Akikazu ^a   Maeda, Ryo ^a   Aokage, Keiju ^a   Hishida, Tomoyuki ^a   Nishimura, Mitsuyo ^a   Nagai, Kanji ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 77958190659     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ec7e70     Document Type: Article

References (18)

1. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 6th Ed. New York, NY: Wiley-Liss, 2002.
2. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:568-577.
3. Nakao M, Yoshida J, Ishii G, et al. Prognostic impact of node involvement pattern in pulmonary pN1 squamous cell carcinoma patients. J Thorac Oncol 2010;5:504-509.
4. Brooks DR, Austin JH, Heelan RT, et al. Influence of type of cigarette on peripheral versus central lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:576-581. (Pubitemid 40489198)
5. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005;130:160-165. (Pubitemid 40941685)
6. Travis WD, Brambilla E, Muller-Hermelink HK, et al. (Eds.), Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IASLC Press, 2004. Pp. 26-76.
7. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978;76:832-839. (Pubitemid 9084851)
8. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-1723. (Pubitemid 27260108)
9. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:1742-1757. (Pubitemid 46755391)
10. van Velzen E, Snijder RJ, Brutel de la Riviere A, et al. Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases. Chest 1996;110:1469-1473. (Pubitemid 26425146)
11. van Velzen E, Snijder RJ, Brutel de la Riviere A, et al. Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. Ann Thorac Surg 1997;63:1436-1440. (Pubitemid 27239739)
12. van Velzen E, de la Riviere AB, Elbers HJ, et al. Type of lymph node involvement and survival in pathologic N1 stage III non-small cell lung carcinoma. Ann Thorac Surg 1999;67:903-907. (Pubitemid 29238271)
13. Marra A, Hillejan L, Zaboura G, et al. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg 2003;125:543-553. (Pubitemid 36373900)
14. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
16. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
17. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-4212.
18. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596. (Pubitemid 44546920)